Institutional members access full text with Ovid®

Share this article on:

Angiogenesis in Non-small Cell Lung Cancer: Imaging With Perfusion Computed Tomography

Ng, Quan Sing MBBS, MRCP*; Goh, Vicky MA, MBBChir, MRCP, FRCR, MD

Journal of Thoracic Imaging: May 2010 - Volume 25 - Issue 2 - p 142-150
doi: 10.1097/RTI.0b013e3181d29ccf
Symposium

Manipulation of tumor vasculature has emerged as a promising therapeutic strategy in advanced non-small cell lung cancer (NSCLC). Bevacizumab has been licensed for first-line therapy in combination with standard chemotherapy in advanced NSCLC, whereas inhibitors of platelet-derived growth factor receptors and other tyrosine kinases are currently in clinical trials for the treatment of advanced NSCLC. Perfusion computed tomography is a promising biomarker in NSCLC. As a measure of tumor perfusion and angiogenesis, perfusion computed tomography may provide invaluable pharmacodynamic information in early-phase clinical trials, monitor the vascular effects of antiangiogenic or vascular-targeting drug treatment, and provide prognostic and predictive information. Current volumetric techniques, affording a coverage of up to 28 cm, permit clinically relevant, high-quality, whole tumor evaluation.

*Department of Medical Oncology, National Cancer Centre, Singapore

Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, United Kingdom

Reprints: Vicky Goh, MA, MBBChir, MRCP, FRCR, MD, Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, United Kingdom (e-mail: vicky.goh@stricklandscanner.org.uk).

© 2010 Lippincott Williams & Wilkins, Inc.